Skip to content
HowShorted

TherapeuticsMD, Inc. short interest in 2019

In 2019, TherapeuticsMD, Inc.'s disclosed short interest ran from 29.27% of shares outstanding on 15 Jan 2019 to 32.02% on 31 Dec 2019, a change of +2.75 percentage points. The year's high was 36.28% on 15 Oct 2019 and its low 29.12% on 29 Nov 2019, averaging 33.09% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 42.53 days on 15 Oct 2019. Full history: TherapeuticsMD, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TherapeuticsMD, Inc. in 2019

2019 in figures

Start of year
29.27% (15 Jan 2019)
End of year
32.02% (31 Dec 2019)
Change
+2.75 pp
High
36.28% (15 Oct 2019)
Low
29.12% (29 Nov 2019)
Average
33.09%
Highest days to cover
42.53 (15 Oct 2019)
SEC filings marked
9

Every report in 2019

TherapeuticsMD, Inc. short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201929.27%21.64
31 Jan 201929.64%30.54
15 Feb 201929.72%24.72
28 Feb 201930.47%15.73results (8-K), 10-K filed
15 Mar 201931.37%26.34
29 Mar 201932.02%34.67
15 Apr 201932.54%40.28
30 Apr 201933.34%28.73
15 May 201934.85%17.38results (8-K), 10-Q filed
31 May 201935.91%30.19
14 Jun 201935.50%15.52
28 Jun 201935.90%23.39
15 Jul 201935.21%40.07
31 Jul 201934.33%32.34
15 Aug 201935.26%17.16results (8-K), 10-Q filed
30 Aug 201935.54%33.93
13 Sep 201934.86%35.26
30 Sep 201936.11%19.95
15 Oct 201936.28%42.53
31 Oct 201935.41%16.22results (8-K)
15 Nov 201930.31%24.88results (8-K), 10-Q filed
29 Nov 201929.12%27.91
13 Dec 201929.27%31.00
31 Dec 201932.02%19.05

See also: TherapeuticsMD, Inc.'s full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.